App-Quantinova.ai

CHEMOKINE PATHWAYS ARE ENRICHED IN PSORIATIC ARTHRITIS (PSA) SKIN LESIONS WITH INCREASED EXPRESSION OF ATYPICAL CHEMOKINE RECEPTOR 2 (ACKR2)

H. Johnsson - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

CHIPPING AWAY AT POLYMYOSITIS: A RETROSPECTIVE REVIEW AT A TERTIARY MYOSITIS CENTRE

J. Loarce-Martos - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

juvenile polymyositis

N/A

CHROMATIN CONFORMATION SIGNATURE ANALYSIS IN EARLY VS LATE SCLERODERMA PHENOTYPES

M. Galloway - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

CLINICAL DISEASE ACTIVITY, MRI SPINAL INFLAMMATION AND ENTHESITIS ARE KEY DETERMINANTS OF IMPAIRMENT OF SPINAL MOBILITY IN EARLY AXIAL SPONDYLOARTHRITIS – DATA FROM THE DESIR COHORT

P. Carvalho - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

CLINICAL PREDICTORS OF SECUKINUMAB RETENTION IN A REAL WORLD COHORT OF PATIENTS WITH PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS

A. Tindell - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Axial spondyloarthritis

secukinumab

CO-EXISTENCE OF SYSTEMIC SCLEROSIS HALLMARK AUTOANTIBODIES ASSOCIATES WITH DISTINCT CLINICAL PHENOTYPE

C. Campochiaro - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

Rituximab

CLINICAL TRIAL DISCRIMINATION OF PHYSICAL FUNCTION INSTRUMENTS FOR PSORIATIC ARTHRITIS: A SYSTEMATIC REVIEW

Y. Y. Leung - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

CLONAL HAEMATOPOIESIS ASSOCIATED SOMATIC MUTATIONS IN RHEUMATOID ARTHRITIS

F. Tariq - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

CLUSTERING OF FRAGILITY FRACTURES BY SITE IN PATIENTS REFERRED FOR BONE MINERAL DENSITY ESTIMATION: AN OBSERVATIONAL STUDY

M. Dey - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

COGNITIVE IMPAIRMENT IN RHEUMATOID ARTHRITIS

C. Edwards - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

COMMUNITY RHEUMATOLOGY SERVICE IN THE UK – WHO BENEFITS THE MOST?

K. Szabo-Kocsis - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

COMPARATIVE DRUG SURVIVAL OF TNF INHIBITORS AND SECUKINUMAB IN BIOLOGIC NAÏVE PATIENTS WITH ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS

M. Cheila - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Ankylosing spondylitis

secukinumab

COMMUNITY ADVISORY BOARD INPUT CAN MAKE LAY SUMMARIES OF CLINICAL TRIAL RESULTS MORE UNDERSTANDABLE

J. Welling - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

COMMON PRACTICE IN DELIVERY OF INTRA-ARTICULAR THERAPIES IN RMDS BY HEALTH PROFESSIONALS: RESULTS FROM A EUROPEAN SURVEY

J. De la Torre-Aboki - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

COMPARATIVE EFFECTIVENESS OF USTEKINUMAB (UST) AND TNF INHIBITORS (TNFI) IN PATIENTS WITH PSORIATIC ARTHRITIS (PSA) IN THE REAL-WORLD, MULTINATIONAL PSABIO STUDY: 12-MONTH FOLLOW-UP

J. S. Smolen - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Ustekinumab

COMPARATIVE EFFECTIVENESS OF JAK-INHIBITORS, TNF-INHIBITORS, ABATACEPT AND IL-6 INHIBITORS IN AN INTERNATIONAL COLLABORATION OF REGISTERS OF RHEUMATOID ARTHRITIS PATIENTS (THE “JAK-POT” STUDY)

K. Lauper - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Abatacept

COMPARATIVE EFFICACY OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS

I. Mcinnes - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

guselkumab (IV)

COMPARATIVE RISK OF CANCER ASSOCIATED WITH FIRST-LINE DMARDS USE IN RHEUMATOID ARTHRITIS: REAL WORLD EVIDENCE FROM THE OHDSI NETWORK

T. Duarte-Salles - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Rheumatoid arthritis

Hydroxychloroquine

COMPARING SYMPTOMS, TREATMENT PATTERNS, AND QUALITY OF LIFE OF ANKYLOSING SPONDYLITIS PATIENTS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IN JAPAN

T. Tomita - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Non-radiographic axial spondyloarthritis

Methadone hydrochloride

COMPARISON OF EFFICACY OF SECUKINUMAB VS ANTI-TNF AS SECOND LINE BIOLOGIC THERAPY IN AXIAL SPONDYLOARTHROPATHY BASED ON BASDAI RESPONSE IN AN OBSERVATIONAL STUDY

O. Weston - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

secukinumab

Filters

45280 Abstracts